Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Nivolumab was first authorized at a weight-based dose (WBD) of 3 mg/kg every two weeks (Q2W). Since 2017, a fixed dose (FD) regimen [first 240 mg Q2W and then 480 mg per month (Q4W)] was allowed. The objective of the study was to compare a WBD regimen and an FD regimen with regard to effectiveness and safety. We conducted a single-center, retrospective, real-life study of consecutive adult patients who had received a WBD of nivolumab or an FD of 480 mg Q4W. The primary endpoint was the occurrence of grade ≥3 immune-related adverse events (irAEs). The secondary endpoints were overall survival and cost of the treatment. In all, 342 patients were included: 71 in the WBD cohort and 271 in the FD cohort. 201 patients (59.6%) experienced an irAE, and 24 of these events were graded as ≥3. At 12 months, there was no significant difference in irAE occurrence between the two cohorts [hazard ratio (95% confidence interval): 0.54 (0.21-1.36), P = 0.19]. The 12-month overall survival rate was significantly lower in the WBD cohort (P < 0.001). Switching from a fortnightly weight dose to a fixed monthly dose halves the cost of hospitalization. Our results did not show a significant difference between WBD and FD cohort in the occurrence of severe irAEs. However Overall survival appeared to be significantly higher in FD group. Some clinical trials are investigating a hybrid dosing regimen in which a WBD is capped by an FD. The present results need to be confirmed in prospective studies.
Identifiants
pubmed: 38489575
doi: 10.1097/CMR.0000000000000965
pii: 00008390-990000000-00137
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 2021; 16:223–249.
Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138–3151.
Korn EL, Liu PY, Lee SJ, Chapman JAW, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26:527–534.
Curti BD, Faries MB. Recent Advances in the Treatment of Melanoma. Longo DL, éditeur. N Engl J Med 2021; 384:2229–2240.
Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltim) 2017; 96:e7325.
Dubois M, Ardin C, André F, Scherpereel A, Mortier L. L’immunothérapie, une révolution en oncologie: Revue de l’efficacité des inhibiteurs de points de contrôle immunitaire. Med Sci (Paris) 2019; 35:937–945.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–723.
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer 2017; 86:37–45.
Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type braf advanced melanoma. J Clin Oncol 2020; 38:3937–3946.
Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017; 28:2002–2008.
Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018; 29:2208–2213.
Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J ImmunoTher Cancer 2017; 5:43.
Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 2020; 131:68–75.
Samlowski W, Robert NJ, Chen L, Schenkel B, Davis C, Moshyk A, et al. Real-world nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Med 2023; 12:2378–2388.
Iikura Y, Aoyama T, Hiraide M, Wakatsuki T, Nakayama I, Ogura M, et al. Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. Health Sci Rep 2022; 5:e673.
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 2018; 18:775–784.
Haute Autorité de Santé. Avis d’efficience. [Opdivo - nivolumab. Traitement adjuvnat du mélanome]. 2019. https://www.has-sante.fr/upload/docs/application/pdf/2019-07/opdivo_16042019_avis_efficience_2019-07-29_15-55-38_800.pdf. [Accessed 20 December 2023]
Haute Autorité de Santé. Avis économique. [Opdivo - nivolumab en association à une chimiothérapie en 1ère ligne, chez les patients atteints d’un carcinome épidermoïde de l’œsophage avancé non résécable, récurrent ou métastatique dont les tumeurs expriment le PD-L1 ≥1%]. 2022. https://www.has-sante.fr/upload/docs/application/pdf/2022-08/opdivo_29032022_avis_economique.pdf. [Accessed 20 December 2023]
Truong J, Yeung SST, Kletas V, de Lemos M, Schaff K, Nakashila L. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer. J Oncol Pharm Pract 2023:10781552231199048.
Zhao X, Shen J, Ivaturi V, Gopalakrishnan M, Feng Y, Schmidt BJ, et al. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. Ann Oncol 2020; 31:302–309.
Malmberg R, Zietse M, Dumoulin DW, Hendrikx JJMA, Aerts JGJV, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol 2022; 23:e552–e561.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res 2019; 38:268.
Bérard G, Guévremont C, Marcotte N, Michel MC, Varin F, Bonnici A, et al. Les inhibiteurs du point de contrôle immunitaire: une stratégie de dosage à privilégier. Pharmactuel 2021; 54:133–135. Disponible sur:https://pharmactuel.com/index.php/pharmactuel/article/view/1413.
Lemieux P, Masse M. Pembrolizumab: implantation de la stratégie posologique de la dose en fonction du poids (mg/kg) jusqu’à la dose maximale. Pharmactuel 2022; 55:44–49.